{"id":"benzbromarone","rwe":[{"pmid":"41865749","year":"2026","title":"A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial.","finding":"","journal":"The Lancet. Rheumatology","studyType":"Clinical Study"},{"pmid":"41814700","year":"2025","title":"[Mechanism study on anti-hyperuricemic effects of Zhejiang Plantaginis Semen glycosides based on metabolomics and metagenomics].","finding":"","journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica","studyType":"Clinical Study"},{"pmid":"41812927","year":"2026","title":"Design, synthesis, and biological evaluation of pyridine-triazole derivatives as URAT1 inhibitors with potential application in hyperuricemia and gout.","finding":"","journal":"Bioorganic & medicinal chemistry letters","studyType":"Clinical Study"},{"pmid":"41787961","year":"2026","title":"Natural products (NPs) for gout treatment in multiple targets and pathways.","finding":"","journal":"British journal of pharmacology","studyType":"Clinical Study"},{"pmid":"41707030","year":"2026","title":"Mechanisms and Targeted Therapeutic Strategies for Inflammation and Renal Fibrosis in Hyperuricemic Nephropathy.","finding":"","journal":"Cell biochemistry and function","studyType":"Clinical Study"}],"tags":[{"label":"benzbromarone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 2C9","category":"target"},{"label":"CYP2C9","category":"gene"},{"label":"SLC22A12","category":"gene"},{"label":"AKR1C1","category":"gene"},{"label":"M04AB03","category":"atc"},{"label":"Active","category":"status"},{"label":"Gout","category":"indication"},{"label":"Hyperuricemia","category":"indication"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Gout Suppressants","category":"pharmacology"},{"label":"Uricosuric Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":87.519,"date":"","count":48,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 48 times (LLR=88)"},{"llr":46.637,"date":"","count":24,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=47)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BENZBROMARONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:48:03.902071+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:48:09.475823+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BENZBROMARONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:48:10.151892+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Solute carrier family 22 member 12 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:48:11.215432+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL388590/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:48:10.863929+00:00"}},"allNames":"azubromaron","offLabel":[],"synonyms":["benzbromarone","benzbromaron","azubromaron"],"timeline":[],"aiSummary":"Benzbromarone, also known as Azubromaron, is a small molecule drug that targets the Cytochrome P450 2C9 enzyme. It is classified as a benzbromarone and is used to treat gout and hyperuricemia. The commercial status of benzbromarone is not specified, but it is likely to be off-patent given its age. As a result, generic manufacturers may be available. Key safety considerations are not well-documented.","brandName":"Azubromaron","ecosystem":[{"indication":"Gout","otherDrugs":[{"name":"allopurinol","slug":"allopurinol","company":"Prometheus Labs"},{"name":"colchicine","slug":"colchicine","company":"Merck"},{"name":"indomethacin","slug":"indomethacin","company":""},{"name":"naproxen","slug":"naproxen","company":"Roche Palo"}],"globalPrevalence":41000000},{"indication":"Hyperuricemia","otherDrugs":[{"name":"allopurinol","slug":"allopurinol","company":"Prometheus Labs"},{"name":"febuxostat","slug":"febuxostat","company":"Takeda Pharms Usa"},{"name":"lesinurad","slug":"lesinurad","company":"Ardea Biosciences Inc"},{"name":"probenecid","slug":"probenecid","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Cytochrome P450 2C9","targets":[{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"},{"gene":"SLC22A12","source":"DrugCentral","target":"Solute carrier family 22 member 12","protein":"Solute carrier family 22 member 12"},{"gene":"AKR1C1","source":"DrugCentral","target":"Aldo-keto reductase family 1 member C1","protein":"Aldo-keto reductase family 1 member C1"},{"gene":"ABCC1","source":"DrugCentral","target":"Multidrug resistance-associated protein 1","protein":"Multidrug resistance-associated protein 1"},{"gene":"ABCG2","source":"DrugCentral","target":"ATP-binding cassette sub-family G member 2","protein":"ATP-binding cassette sub-family G member 2"},{"gene":"PDE4A","source":"DrugCentral","target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A","protein":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"MAPK14","source":"DrugCentral","target":"Mitogen-activated protein kinase 14","protein":"Mitogen-activated protein kinase 14"},{"gene":"MAPK1","source":"DrugCentral","target":"Mitogen-activated protein kinase 1","protein":"Mitogen-activated protein kinase 1"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3"}],"modality":"Small Molecule","drugClass":"benzbromarone","explanation":"","oneSentence":"","technicalDetail":"Benzbromarone specifically inhibits the activity of the cytochrome P450 2C9 enzyme, which is involved in the metabolism of uric acid. By inhibiting this enzyme, benzbromarone reduces the production of uric acid and increases its excretion, thereby lowering serum uric acid levels."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/318","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BENZBROMARONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BENZBROMARONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:56:32.322705","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:12.489054+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"probenecid","drugSlug":"probenecid","fdaApproval":"1951-04-26","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sulfinpyrazone","drugSlug":"sulfinpyrazone","fdaApproval":"1959-05-13","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"lesinurad","drugSlug":"lesinurad","fdaApproval":"2015-12-22","patentExpiry":"Nov 26, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"benzbromarone","indications":{"approved":[{"name":"Gout","source":"DrugCentral","snomedId":90560007,"regulator":"FDA","usPrevalence":9200000,"globalPrevalence":41000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Hyperuricemia","source":"DrugCentral","snomedId":35885006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"probenecid","brandName":"probenecid","genericName":"probenecid","approvalYear":"1951","relationship":"same-class"},{"drugId":"sulfinpyrazone","brandName":"sulfinpyrazone","genericName":"sulfinpyrazone","approvalYear":"1959","relationship":"same-class"},{"drugId":"lesinurad","brandName":"lesinurad","genericName":"lesinurad","approvalYear":"2015","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06966635","phase":"PHASE4","title":"Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-04-10","conditions":["Hyperuricemia or Gout","Nephrolithiasis"],"enrollment":312,"completionDate":"2026-04-30"},{"nctId":"NCT05504083","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2022-09-28","conditions":["Hyperuricemia"],"enrollment":121,"completionDate":"2024-05-18"},{"nctId":"NCT06582654","phase":"","title":"Normalizing Antibody Detection in First-void Urine","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2023-12-07","conditions":["Human Papillomavirus Infection"],"enrollment":150,"completionDate":"2026-01-01"},{"nctId":"NCT05210517","phase":"PHASE4","title":"SGLT2 Inhibition: Uric Acid Excretion Study","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-10-01","conditions":["Type 2 Diabetes"],"enrollment":10,"completionDate":"2021-09-01"},{"nctId":"NCT04213534","phase":"","title":"The Influence of Urate-lowering Therapy on Sperm Quality of Male Gouty Patients：A Prospective Cohort Study","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2020-10-10","conditions":["Gout"],"enrollment":60,"completionDate":"2023-12"},{"nctId":"NCT03534037","phase":"PHASE4","title":"Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction","status":"UNKNOWN","sponsor":"National Defense Medical Center, Taiwan","startDate":"2020-02-01","conditions":["Hyperuricemia","Metabolic Syndrome","Left Ventricular Diastolic Dysfunction"],"enrollment":120,"completionDate":"2021-12"},{"nctId":"NCT03185793","phase":"PHASE2","title":"Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-07-20","conditions":["Hyperuricemia"],"enrollment":198,"completionDate":"2018-07-20"},{"nctId":"NCT02338323","phase":"NA","title":"Compare the Renal Protective Effects of Febuxostat and Benzbromarone","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2015-01","conditions":["Chronic Kidney Disease","Hyperuricemia","Abnormal Renal Function"],"enrollment":160,"completionDate":"2018-12"},{"nctId":"NCT03100318","phase":"PHASE3","title":"Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2017-04-01","conditions":["Hyperuricemia With or Without Gout"],"enrollment":201,"completionDate":"2018-08-31"},{"nctId":"NCT02790450","phase":"PHASE2","title":"Acute Effects of Benzbromaron on the Pulmonary Circulation","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2015-10","conditions":["Idiopathic Pulmonary Arterial Hypertension"],"enrollment":10,"completionDate":"2016-08"},{"nctId":"NCT02944214","phase":"NA","title":"Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients","status":"UNKNOWN","sponsor":"Shanghai 10th People's Hospital","startDate":"2016-10","conditions":["Chronic Kidney Disease","Hyperuricemia","Abnormal Renal Function"],"enrollment":800,"completionDate":"2019-12"},{"nctId":"NCT02317861","phase":"PHASE1,PHASE2","title":"A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":["Gout and Asymptomatic Hyperuricemia"],"enrollment":110,"completionDate":"2015-06"},{"nctId":"NCT00422318","phase":"PHASE4","title":"Treatment of Hyperuricemia in Patients With Heart Failure","status":"COMPLETED","sponsor":"Tottori University Hospital","startDate":"2004-01","conditions":["Heart Failure","Hyperuricemia"],"enrollment":0,"completionDate":"2005-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000166974","NDDF":"005311","UNII":"4POG0RL69O","CHEBI":"CHEBI:3023","INN_ID":"1427","RXNORM":"1385","UMLSCUI":"C0005035","chemblId":"CHEMBL388590","ChEMBL_ID":"CHEMBL388590","KEGG_DRUG":"D01056","DRUGBANK_ID":"DB12319","PDB_CHEM_ID":" R75","PUBCHEM_CID":"2333","SNOMEDCT_US":"698025001","MESH_DESCRIPTOR_UI":"D001553"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":725,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"M04AB03","allCodes":["M04AB03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 19","pmid":"41865749","title":"A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial.","journal":"The Lancet. Rheumatology"},{"date":"2025 Dec","pmid":"41814700","title":"[Mechanism study on anti-hyperuricemic effects of Zhejiang Plantaginis Semen glycosides based on metabolomics and metagenomics].","journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica"},{"date":"2026 Mar 10","pmid":"41812927","title":"Design, synthesis, and biological evaluation of pyridine-triazole derivatives as URAT1 inhibitors with potential application in hyperuricemia and gout.","journal":"Bioorganic & medicinal chemistry letters"},{"date":"2026 Mar 6","pmid":"41787961","title":"Natural products (NPs) for gout treatment in multiple targets and pathways.","journal":"British journal of pharmacology"},{"date":"2026 Feb","pmid":"41707030","title":"Mechanisms and Targeted Therapeutic Strategies for Inflammation and Renal Fibrosis in Hyperuricemic Nephropathy.","journal":"Cell biochemistry and function"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:12.489054+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}